Sunshine Biopharma, Inc.

NasdaqCM SBFM

Sunshine Biopharma, Inc. EPS (Diluted) for the year ending December 31, 2023: USD -370.41

Sunshine Biopharma, Inc. EPS (Diluted) is USD -370.41 for the year ending December 31, 2023, a 89.49% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Sunshine Biopharma, Inc. EPS (Diluted) for the year ending December 31, 2022 was USD -3,523.64, a 63.95% change year over year.
  • Sunshine Biopharma, Inc. EPS (Diluted) for the year ending December 31, 2021 was USD -9,774.32.
  • Sunshine Biopharma, Inc. EPS (Diluted) for the year ending December 31, 2019 was USD -828.01, a -485.00% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
NasdaqCM: SBFM

Sunshine Biopharma, Inc.

CEO Dr. Steve N. Slilaty Ph.D.
IPO Date Feb. 15, 2022
Location Canada
Headquarters 6500 Trans-Canada Highway
Employees 44
Sector Health Care
Industries
Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

Similar companies

SNOA

Sonoma Pharmaceuticals, Inc.

USD 2.64

2.33%

LFCR

Lifecore Biomedical, Inc.

USD 6.43

1.10%

DERM

Journey Medical Corporation

USD 3.73

-1.32%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

TKNO

Alpha Teknova, Inc.

USD 7.91

-2.10%

StockViz Staff

January 16, 2025

Any question? Send us an email